All patients with urothelial carcinoma and cholangiocarcinoma who responded to erdafitinib carried FGFR mutations or fusions. The ORR in the all treated urothelial carcinoma population was 12 of 30 (40%), and 12 of 26 (46%) in the FGFR mutation and fusion-positive population. For urothelial carcinoma patients, 10 were treated with continuous dosing (9 mg daily), and 16 were treated with intermittent schedule (15 at 10 mg and 1 at 12 mg) and the response rate was numerically higher at 70% with 9 mg daily than 32% with intermittent dosing (Table 4; Fig. 1A).